AI Article Synopsis
- Allergic inflammation is linked to a higher risk of viral infections, with the study aiming to determine if omalizumab can reduce rhinovirus (RV) illnesses in children with allergic asthma.
- In a study involving 478 children, those treated with omalizumab showed decreased duration and frequency of RV infections compared to those receiving standard asthma care.
- The results indicate that omalizumab effectively reduces the risk of RV illnesses by targeting IgE, confirming its role in improving outcomes for children with allergic asthma.
Article Abstract
Rationale: Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal.
Objectives: To test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus (RV) illnesses in children with allergic asthma.
Methods: In the PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examined children with allergic asthma (aged 6-17 yr; n = 478) from low-income census tracts in eight U.S. cities, and we analyzed virology for the groups randomized to treatment with guidelines-based asthma care (n = 89) or add-on omalizumab (n = 259). Weekly nasal mucus samples were analyzed for RVs, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during the fall seasons of 2012 or 2013. Adjusted illness rates (illnesses per sample) by treatment arm were calculated using Poisson regression.
Measurements And Main Results: RVs were detected in 97 (57%) of 171 exacerbation samples and 2,150 (36%) of 5,959 nonexacerbation samples (OR, 2.32; P < 0.001). Exacerbations were significantly associated with detection of rhinovirus C (OR, 2.85; P < 0.001) and rhinovirus A (OR, 2.92; P < 0.001), as well as, to a lesser extent, rhinovirus B (OR, 1.98; P = 0.019). Omalizumab decreased the duration of RV infection (11.2 d vs. 12.4 d; P = 0.03) and reduced peak RV shedding by 0.4 log units (95% confidence interval, -0.77 to -0.02; P = 0.04). Finally, omalizumab decreased the frequency of RV illnesses (risk ratio, 0.64; 95% confidence interval, 0.49-0.84).
Conclusions: In children with allergic asthma, treatment with omalizumab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses. These findings provide direct evidence that blocking IgE decreases susceptibility to RV infections and illness. Clinical trial registered with www.clinicaltrials.gov (NCT01430403).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649984 | PMC |
| http://dx.doi.org/10.1164/rccm.201701-0120OC | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rhinoconjunctivitis Symptoms in Children and Adolescents with Asthma: A Longitudinal Clustering Analysis.
J Allergy Clin Immunol
January 2025
Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI.
Background: Rhinoconjunctivitis phenotypes are conventionally described based on symptom severity, duration and seasonality and aeroallergen sensitization. It is not known whether these phenotypes fully reflect the patterns of symptoms seen at a population level.
Objective: To identify phenotypes of rhinoconjunctivitis based on symptom intensity and seasonality using an unbiased approach and to compare their characteristics.
Natural history of sesame allergy in pediatric patients: Insight from a retrospective analysis.
Pediatr Allergy Immunol
January 2025
Department of Pediatric Allergy, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Background: Sesame allergy (SA) is a growing concern because of its association with severe reactions and the limited knowledge of long-term outcomes.
Objective: This retrospective study aimed to identify the risk factors influencing persistent SA (PSA) in children to improve management and select suitable candidates for oral immunotherapy (OIT).
Methods: We analyzed the electronic medical records of 84 children with confirmed SA, as defined by consistent clinical reactions and immunoglobulin E (IgE)-mediated sensitization.
Clinical and Laboratory Characteristics and Comorbidities in Asthma Endotypes in Children.
Indian Pediatr
January 2025
Community and Family Medicine, All India Institute of Medical Sciences, Deoghar, Jharkhand, India.
Objective: To estimate the proportion of eosinophilic and non-eosinophilic (NEA) endotypes in pediatric asthma, and to compare the clinical, and laboratory characterisitics, and different comorbidities between the two endotypes in the children.
Methods: Children aged 5 to 14 years of age with clinical and/or laboratory-confirmed asthma attending the pediatric outpatient department of a tertiary care hospital in Eastern India between October 1, 2023 and March 31, 2024, were included in this cross-sectional study. Complete hemogram, absolute eosinophil count (AEC), IgE, and pulmonary function tests were performed in all patients.
Social Determinants' Role in Pediatric Respiratory Health: Health Insights from Central Florida.
South Med J
January 2025
Department of Allergy and Immunology, Nemours Children's Health, Orlando, Florida.
Objectives: Despite advances in therapies and educational initiatives, pediatric allergy disorders, including asthma, allergic rhinitis, and eczema, continue to pose substantial health challenges. Understanding the social determinants of health (SDoH) linked with these conditions is a critical area of research due to their multifactorial nature. This study aimed to assess the SDoH influencing pediatric allergy disorders in central Florida, specifically examining four groups of children: with asthma only, with eczema only, with both asthma and eczema, and a control group without these conditions.
View Article and Find Full Text PDF[Contact dermatitis in children].
Ugeskr Laeger
December 2024
Hudafdeling I og Allergicentret, Odense Universitetshospital.
Article Synopsis
- Contact dermatitis is a frequent skin issue in children, resulting from exposure to irritants or allergens in their environment.
- Diagnosis involves assessing symptoms, dermatitis patterns, and a patient's exposure history, with patch testing being the most reliable method to differentiate allergic from irritant contact dermatitis.
- The review focuses on understanding contact dermatitis in children, covering how to diagnose it, differentiate it from other conditions, and strategies for managing it.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!